Taxotere | The American Association For Justice

Taxotere

Description:

The chemotherapy drug Taxotere/Docetaxel was marketed to women as a more effective drug to treat breast cancer. Taxotere’s manufacturer failed to disclose what it knew to be a disfiguring side effect of the drug, namely permanent irreversible hair loss, to women in the United States. However, this side effect was disclosed to women in Europe since 2005. The FDA mandated a label change in the United States effective January 2016, but there are thousands of women who have taken this drug and not been advised of this consequence. There was and is an equally effective drug on the market that does not have this severe side effect.

The Taxotere Litigation Group acts as a platform for members in to discuss litigation and share research and expert information.

The Taxotere Litigation Group is sponsored by CAMG


Benefits & Resources:

Members of the group have access to a secure, members-only list server and document library, as well as meeting and education programs throughout the year.

Cochairs:
J. Kyle Bachus
Bachus & Schanker, LLC
1899 Wynkoop St.
Suite 700
Denver, CO 80202
Phone: 303/996-9823
 
Karen Barth Menzies
Gibbs Law Group LLP
7812 Veragua Dr.
Playa del Rey, CA 90293
Phone: 510/350-9240
 
Jessica Perez
Pendley Baudin & Coffin, LLP
PO Drawer 71
Plaquemine, LA 70765
Phone: 888/725-2477
PDF Application: